KR101869413B1 - Ｓ100ａ4 항체들 및 이들의 치료 용도 - Google Patents

Ｓ100ａ4 항체들 및 이들의 치료 용도 Download PDF

Info

Publication number
KR101869413B1
KR101869413B1 KR1020137000997A KR20137000997A KR101869413B1 KR 101869413 B1 KR101869413 B1 KR 101869413B1 KR 1020137000997 A KR1020137000997 A KR 1020137000997A KR 20137000997 A KR20137000997 A KR 20137000997A KR 101869413 B1 KR101869413 B1 KR 101869413B1
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
ecacc
protein
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137000997A
Other languages
English (en)
Korean (ko)
Other versions
KR20130137583A (ko
Inventor
호세 루이스 헤르난데즈 미구에쓰
자움 아단 플라나
조셉 마리아 마르티네쓰 에스꼴라
마르크 마사 알바레쓰
라몬 메쎄구에르 뻬예포츠
프란쎄스끄 미뜨한스 프라뜨
쉴라 다켈 쁠라자
안토니오 꼴 만짜노
로사 엠에이 헤르바스 빌레가스
까르메 깔비스 칼페
라우라 빠딜라 가르시아
로우르데스 타티아나 로꾸에 나바로
라우라 바르베라 페르란도
마뉴엘 리바스 까나스
루이스 엔젤 고메즈 까사후스
Original Assignee
리케라 바이오메드 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43617041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101869413(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리케라 바이오메드 에스에이 filed Critical 리케라 바이오메드 에스에이
Publication of KR20130137583A publication Critical patent/KR20130137583A/ko
Application granted granted Critical
Publication of KR101869413B1 publication Critical patent/KR101869413B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
KR1020137000997A 2010-06-14 2011-06-14 Ｓ100ａ4 항체들 및 이들의 치료 용도 Expired - Fee Related KR101869413B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382170 2010-06-14
EP10382170.8 2010-06-14
PCT/EP2011/059868 WO2011157724A1 (en) 2010-06-14 2011-06-14 S100a4 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
KR20130137583A KR20130137583A (ko) 2013-12-17
KR101869413B1 true KR101869413B1 (ko) 2018-06-20

Family

ID=43617041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137000997A Expired - Fee Related KR101869413B1 (ko) 2010-06-14 2011-06-14 Ｓ100ａ4 항체들 및 이들의 치료 용도

Country Status (22)

Country Link
US (2) US8916152B2 (https=)
EP (1) EP2580240B1 (https=)
JP (2) JP6081911B2 (https=)
KR (1) KR101869413B1 (https=)
CN (1) CN103201290B (https=)
AU (3) AU2011267089B2 (https=)
BR (1) BR112012032008B1 (https=)
CA (1) CA2802631C (https=)
CL (1) CL2012003538A1 (https=)
CY (1) CY1121742T1 (https=)
DK (1) DK2580240T3 (https=)
ES (1) ES2717908T3 (https=)
IL (1) IL223667B (https=)
LT (1) LT2580240T (https=)
MX (1) MX347734B (https=)
NZ (1) NZ604643A (https=)
PL (1) PL2580240T4 (https=)
PT (1) PT2580240T (https=)
RU (1) RU2615684C2 (https=)
SM (1) SMT201900219T1 (https=)
TR (1) TR201903026T4 (https=)
WO (1) WO2011157724A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2580240T (pt) * 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
RU2484096C1 (ru) * 2012-02-08 2013-06-10 Общество с ограниченной ответственностью "Технофарма" ОДНОДОМЕННОЕ АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ БЕЛОК S100A4/Mts1, ПРИМЕНЕНИЕ ПОЛУЧЕННОГО АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ ЭТОГО БЕЛКА
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
JP2014094919A (ja) * 2012-11-09 2014-05-22 Univ Of Fukui 腎炎の予防または治療剤
JP6183920B2 (ja) * 2012-11-09 2017-08-23 国立大学法人福井大学 腎炎の病変部位の検査方法およびそのための試薬
US9914768B2 (en) 2013-04-09 2018-03-13 Lykera Biomed, S.A. Anti-S100A7 antibodies for the treatment and diagnosis of cancer
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
CN112083167B (zh) * 2019-06-14 2024-03-26 复旦大学附属华山医院 S100a4作为评估甲氨蝶呤干预银屑病的生物标记物及其用途
EP3999531A1 (en) * 2019-07-15 2022-05-25 University of Connecticut Metallothionein antibodies and their use
KR102151133B1 (ko) * 2019-12-27 2020-09-02 주식회사 인투앱 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
JP2023531230A (ja) * 2020-06-30 2023-07-21 アークス セラピューティクス エーエス 全身性硬化症の治療のための抗ｓ１００ａ４抗体
IL304971A (en) 2021-02-09 2023-10-01 Arxx Therapeutics As Humanized anti-S100A4 antibody, uses and methods
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
EP4433084A1 (en) 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020656A1 (en) * 1994-01-31 1995-08-03 Research Corporation Technologies, Inc. Diagnosis of metastatic cancer by the mts-1 gene
WO2000064475A1 (en) * 1999-04-23 2000-11-02 Research Corporation Technologies, Inc. Treatment of metastatic cancer through mts-1 gene
WO2007071248A2 (en) * 2005-12-20 2007-06-28 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP3398149B2 (ja) * 1990-07-09 2003-04-21 リサーチ コーポレーション テクノロジーズ インコーポレーテッド Ｍｔｓ―１遺伝子による転移性の癌の診断
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
JP2002542297A (ja) * 1999-04-23 2002-12-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 血管形成を増強するための治療組成物および方法
DE10017249A1 (de) 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
AU2002347182A1 (en) 2001-12-18 2003-06-30 Mondobiotech Licensing Out Ag Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
JP2005532036A (ja) 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
US20040157278A1 (en) 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
US20050208518A1 (en) 2003-05-16 2005-09-22 Longueville Francoise D Method and apparatus for determination of RNAi cell transfection effects by multiple gene expression analysis on micro-arrays
US20040229225A1 (en) 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
ATE419392T1 (de) 2003-07-04 2009-01-15 Johnson & Johnson Res Pty Ltd Verfahren zum nachweis von alkyliertem cytosin in dna
CA2534456A1 (en) 2003-08-01 2005-02-10 The University Of Western Australia Methods and kits for predicting the likelihood of successful treatment of cancer
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
JP2007537717A (ja) 2004-01-07 2007-12-27 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2006052795A2 (en) 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
KR100664589B1 (ko) 2004-12-28 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 및이를 포함하는 발현 벡터
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20060269948A1 (en) 2005-05-16 2006-11-30 Halloran Philip F Tissue rejection
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
CN101365806B (zh) 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
TW200745556A (en) 2006-01-24 2007-12-16 Ind Tech Res Inst Biomarkers for liver fibrotic injury
JP2007263896A (ja) 2006-03-29 2007-10-11 Univ Nagoya 肺癌患者の術後予後予測のための生物マーカー及びその方法
WO2007126391A1 (en) 2006-04-28 2007-11-08 Singapore Health Services Pte Ltd Investigation of mucosa dryness conditions
WO2008030278A2 (en) 2006-06-05 2008-03-13 Fred Hutchinson Cancer Research Center Assays for radiation exposure
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008037432A2 (en) 2006-09-27 2008-04-03 Charité - Universitätsmedizin Berlin METHODS FOR DIAGNOSING METASTASIS BY ANALYZING MUTATIONS IN β-CATENIN
US20100248225A1 (en) 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
DE102006056784A1 (de) 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
WO2008073290A1 (en) 2006-12-08 2008-06-19 The Board Of Trustees Of The University Of Arkansas Tp53 gene expression and uses thereof
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
US20080161203A1 (en) 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
US20100120788A1 (en) 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
EP2155897A2 (en) 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
CA2682827A1 (en) 2007-04-05 2008-10-16 Source Precision Medicine, Inc., D/B/A Source Mdx Gene expression profiling for identification, monitoring and treatment of ovarian cancer
AU2007353824A1 (en) 2007-04-06 2008-11-27 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US20090093005A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
PT2580240T (pt) * 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020656A1 (en) * 1994-01-31 1995-08-03 Research Corporation Technologies, Inc. Diagnosis of metastatic cancer by the mts-1 gene
WO2000064475A1 (en) * 1999-04-23 2000-11-02 Research Corporation Technologies, Inc. Treatment of metastatic cancer through mts-1 gene
WO2007071248A2 (en) * 2005-12-20 2007-06-28 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins

Also Published As

Publication number Publication date
US9657092B2 (en) 2017-05-23
EP2580240A1 (en) 2013-04-17
LT2580240T (lt) 2019-06-10
US8916152B2 (en) 2014-12-23
CN103201290B (zh) 2016-09-28
DK2580240T3 (en) 2019-03-25
RU2615684C2 (ru) 2017-04-06
CL2012003538A1 (es) 2014-02-14
BR112012032008A2 (pt) 2016-10-04
SMT201900219T1 (it) 2019-05-10
AU2017200281B2 (en) 2018-12-06
ES2717908T3 (es) 2019-06-26
AU2018264107A1 (en) 2018-12-06
RU2013101529A (ru) 2014-07-20
PT2580240T (pt) 2019-03-29
PL2580240T3 (pl) 2020-03-31
EP2580240B1 (en) 2018-11-28
CA2802631C (en) 2019-12-17
AU2011267089B2 (en) 2017-02-16
CN103201290A (zh) 2013-07-10
NZ604643A (en) 2015-04-24
CY1121742T1 (el) 2020-07-31
US20150079097A1 (en) 2015-03-19
CA2802631A1 (en) 2011-12-22
JP6081911B2 (ja) 2017-02-15
IL223667B (en) 2018-03-29
MX347734B (es) 2017-05-11
KR20130137583A (ko) 2013-12-17
WO2011157724A1 (en) 2011-12-22
PL2580240T4 (pl) 2020-03-31
MX2012014678A (es) 2013-02-26
JP6564408B2 (ja) 2019-08-21
BR112012032008B1 (pt) 2020-05-26
US20130101592A1 (en) 2013-04-25
AU2011267089A1 (en) 2013-01-17
JP2017101050A (ja) 2017-06-08
AU2017200281A1 (en) 2017-02-02
TR201903026T4 (en) 2019-04-22
JP2013531655A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
KR101869413B1 (ko) Ｓ100ａ4 항체들 및 이들의 치료 용도
TWI775781B (zh) 癌症之治療性及診斷性方法
WO2021254481A9 (zh) 抗Claudin18.2抗体以及其用途
CN109196121A (zh) 用于癌症的治疗和诊断方法
HK1250376A1 (zh) 用於癌症的治疗和诊断方法
CN113196061A (zh) 肉瘤样肾癌的诊断和治疗方法
EP2984108B1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
TWI743469B (zh) 抗ｇｉｔｒ抗體及其用途
EP4471057A1 (en) Anti-human cxcl1 antibody
JP2023523450A (ja) 非小細胞肺がん免疫療法のための方法及び組成物
US20150152193A1 (en) Axl antibodies
HK40053242A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
HK40016679A (en) Therapeutic and diagnostic methods for cancer
HK1234432B (en) Antibodies that specifically block the biological activity of a tumor antigen

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20210609

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20220603

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240615

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240615